# Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

> **NCT07324473** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Chongqing Medical University** · enrollment: 65 (estimated)

## Conditions studied

- Hepatocellular Carcinomas
- Resistance to Immunotherapy
- Immunomodulation
- Drug Repurposing

## Interventions

- **DRUG:** The triple-therapy strategy of Ivarmacitinib, Apatinib, and Camrelizumab

## Key facts

- **NCT ID:** NCT07324473
- **Lead sponsor:** First Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324473, "Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07324473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*